PDUFA VII Commitment Letter Outlines Real-Time Review Expansion, Hiring Goals
Executive Summary
Allergenic extract products, previously excluded, also will become part of the user fee program beginning in FY 2023.
You may also be interested in...
US FDA Chief Of Staff Returning To CBER For Deputy Director Role
Julie Tierney will become CBER’s deputy director for strategy, policy and legislation, a newly created position.
Heritable Genetic Modification Debate May Ignite Again As Technology Advances
CBER Director Peter Marks said the US may have to consider whether to maintain its ban on the practice of creating embryos to include heritable genetic modifications if other countries allow the practice.
Pilot Phase Of Operation Warp Speed For Rare Diseases Beginning Soon
US FDA’s biologics center intends to ask for volunteers to help demonstrate the concept, modeled on the COVID vaccine effort, which includes speedier communication with sponsors to expedite development of products for rare diseases.